AIM ImmunoTech Secures Key Japanese Patent for Ampligen in Cancer Therapy—Focus on Pancreatic Cancer
Market Chameleon (Wed, 18-Mar 9:51 AM)
AIM ImmunoTech’s Phase 2 Data Suggests Survival Advantage and High Quality of Life in Pancreatic Cancer Patients
Market Chameleon (Thu, 5-Feb 9:52 AM)
